Research programme: heavy metal poisoning therapeutics - Medesis Pharma

Drug Profile

Research programme: heavy metal poisoning therapeutics - Medesis Pharma

Alternative Names: Americium decorporation - Medesis Pharma; Curium decorporation - Medesis Pharma; NU 01; NU 02; NU 03

Latest Information Update: 12 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medesis Pharma
  • Developer CEA; Medesis Pharma
  • Class
  • Mechanism of Action Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Heavy metal poisoning

Most Recent Events

  • 12 Aug 2016 Preclinical development is ongoing for Heavy metal poisoning (Medesis pipeline, August 2016)
  • 26 Mar 2014 Medesis Pharma and CEA enter into a collaboration for development of compounds for Heavy metal poisoning
  • 19 Feb 2014 Medesis Pharma and CEA file for patent protection for decorporation process for distribution of chelators using the Aonys®
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top